The primary aim of the autumn 2024 COVID-19 vaccination programme remains the prevention of severe illness, hospitalisations, and deaths, arising from COVID-19. On 2 August 2024 the Government accepted the advice of the independent Joint Committee on Vaccination and Immunisation (JCVI) to offer a COVID-19 vaccination to those aged 65 years old or over, those living in care homes for older adults, and those aged between six months and 64 years old who are in a clinical risk group in England this autumn. Additionally, vaccination will be offered to all frontline health and social care workers, as well as staff in care homes for older adults.<\/p>
There are no plans to offer a COVID-19 vaccination to unpaid carers, including young carers, or the families and household contacts of people with immunosuppression, during the autumn 2024 campaign in England. Unpaid carers and household contacts of those with immunosuppression have previously been offered vaccination on the basis that it indirectly protected those more vulnerable with whom they are in contact.\u202fThe JCVI advice for autumn 2024 is that in the era of highly transmissible Omicron sub-variants, any protection offered by the vaccines against transmission of infection from one person to another is expected to be extremely limited. The indirect benefits of vaccination in these groups, vaccinating an individual to reduce the risk of severe disease in other people, are therefore less evident than in previous years.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"} , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"} , "dateOfAnswer" : {"_value" : "2024-09-06", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "3147"} , {"_value" : "3570"} , {"_value" : "3782"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-09-06T14:36:09.307Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-08-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will include (a) unpaid family carers and (b) household contacts of immuno-suppressed individuals in the covid-19 vaccination programme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : "http://data.parliament.uk/members/5359", "tablingMemberConstituency" : {"_value" : "Poole"} , "tablingMemberPrinted" : [{"_value" : "Neil Duncan-Jordan"} ], "uin" : "3660"} , {"_about" : "http://data.parliament.uk/resources/1726351", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1726351/answer", "answerText" : {"_value" : "
We understand how important it is to patients and their families that they are able to benefit from access to innovative treatments that can slow down the effects of this complex disease.<\/p>
Decisions on whether new medicines should be routinely funded by the National Health Service are made independently by the National Institute for Health and Care Excellence (NICE) on the basis of the evidence of costs and benefits. The methods and processes that NICE uses are internationally respected and have been developed through extensive engagement with academics, industry, patients and clinicians, to ensure that they reflect best practice and societal preferences.<\/p>
NICE is currently developing guidance for the NHS on the use of lecanemab and recently published draft guidance for consultation that does not recommend it as a clinically and cost-effective use of NHS resources. We recognise that NICE\u2019s draft decision will be disappointing, but it is right that these decisions are made independently based on the available evidence of their costs and benefits. NICE has not yet published final guidance and stakeholders now have an opportunity to comment on NICE\u2019s draft recommendations.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"} } , "answeringMemberConstituency" : {"_value" : "Bristol South"} , "answeringMemberPrinted" : {"_value" : "Karin Smyth"} , "dateOfAnswer" : {"_value" : "2024-09-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-09-09T10:19:02.51Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-08-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lecanemab"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to make Lecanemab available on the NHS to patients with early onset Alzheimer\u2019s disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : "http://data.parliament.uk/members/5359", "tablingMemberConstituency" : {"_value" : "Poole"} , "tablingMemberPrinted" : [{"_value" : "Neil Duncan-Jordan"} ], "uin" : "3664"} , {"_about" : "http://data.parliament.uk/resources/1724060", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1724060/answer", "answerText" : {"_value" : "
The Department is currently considering next steps to improve access to autism assessments. We expect integrated care boards (ICBs) to have due regard to relevant National Institute for Health and Care Excellence (NICE) guidelines on autism, when commissioning services for children, young people, and adults. It is the responsibility of ICBs to make available appropriate provision to meet the health and care needs of their local population, in line with these NICE guidelines.<\/p>
On 5 April 2023, NHS England published a national framework and operational guidance to deliver improved outcomes in all-age autism assessment pathways. This guidance will help ICBs and the National Health Service to deliver improved outcomes for children, young people, and adults referred to an autism assessment service. In 2024/25, £4.3 million is available nationally to improve services for autistic children and young people, including autism assessment services.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4359", "label" : {"_value" : "Biography information for Stephen Kinnock"} } , "answeringMemberConstituency" : {"_value" : "Aberafan Maesteg"} , "answeringMemberPrinted" : {"_value" : "Stephen Kinnock"} , "dateOfAnswer" : {"_value" : "2024-09-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-09-02T11:59:55.013Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-07-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Autism: Diagnosis"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce waiting times for children requiring an autism assessment.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"} , "tablingMember" : "http://data.parliament.uk/members/5359", "tablingMemberConstituency" : {"_value" : "Poole"} , "tablingMemberPrinted" : [{"_value" : "Neil Duncan-Jordan"} ], "uin" : "2221"} , {"_about" : "http://data.parliament.uk/resources/485534", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/485534/answer", "answerText" : {"_value" : "
The Department assesses the impact of all proposed measures before laying legislation using standard government methodology. These assessments are set out in Impact Assessments which are scrutinised by the Regulatory Policy Committee before publication alongside the Statutory Instrument. Impact Assessments include a thorough analysis of the costs, benefits and risks associated with policy options.<\/p>
A number of the tobacco measures contain commitments to further review the impact of the legislation within five years of them coming into force.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2016-04-11", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "32264"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-04-11T08:49:14.093Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2016-03-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Tobacco"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what the cumulative loss in revenue to HM Treasury has been as a result of the effect of tobacco control measures over the last 10 years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/245", "label" : {"_value" : "Biography information for Sir Robert Syms"} } , "tablingMemberConstituency" : {"_value" : "Poole"} , "tablingMemberPrinted" : [{"_value" : "Mr Robert Syms"} ], "uin" : "32263"} , {"_about" : "http://data.parliament.uk/resources/485535", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/485535/answer", "answerText" : {"_value" : "
The Department assesses the impact of all proposed measures before laying legislation using standard government methodology. These assessments are set out in Impact Assessments which are scrutinised by the Regulatory Policy Committee before publication alongside the Statutory Instrument. Impact Assessments include a thorough analysis of the costs, benefits and risks associated with policy options.<\/p>
A number of the tobacco measures contain commitments to further review the impact of the legislation within five years of them coming into force.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2016-04-11", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "32263"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-04-11T08:49:14.157Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2016-03-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Tobacco: EU Law"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the potential reduction in revenue to the public purse resulting from the EU Tobacco Products Directive.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/245", "label" : {"_value" : "Biography information for Sir Robert Syms"} } , "tablingMemberConstituency" : {"_value" : "Poole"} , "tablingMemberPrinted" : [{"_value" : "Mr Robert Syms"} ], "uin" : "32264"} , {"_about" : "http://data.parliament.uk/resources/485645", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/485645/answer", "answerText" : {"_value" : "
The Government has no current plans to postpone the introduction of standardised packaging of tobacco products. The Standardised Packaging of Tobacco Products Regulations 2015 come into force on 20 May 2016. Standardised packaging is an important public health measure and any delay in implementing the policy would also delay the health benefits from accruing. The Government continues to consider relevant information and evidence on standardised packaging, including the Post-Implementation Review of Tobacco Plain Packaging published by the Australian Government last month.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2016-04-11", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-04-11T08:52:56.44Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2016-03-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Tobacco: Packaging"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, if he will postpone the start date for the introduction of standardised packaging on tobacco products in order to undertake an assessment of the implications of the post-implementation review of a similar measure in Australia on his policies in this area.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/245", "label" : {"_value" : "Biography information for Sir Robert Syms"} } , "tablingMemberConstituency" : {"_value" : "Poole"} , "tablingMemberPrinted" : [{"_value" : "Mr Robert Syms"} ], "uin" : "32266"} , {"_about" : "http://data.parliament.uk/resources/485716", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/485716/answer", "answerText" : {"_value" : "
Discussions are ongoing between Departmental officials and the relevant authorities about enforcement action. Guidance on the enforcement process has been sent to police forces and, as with other smokefree legislation, we expect high levels of compliance with this change.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2016-04-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-04-13T11:51:32.073Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2016-03-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Motor Vehicles: Smoking"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what discussions his Department has had with police forces on the level of enforcement of legislation on smoking in vehicles with children present; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/245", "label" : {"_value" : "Biography information for Sir Robert Syms"} } , "tablingMemberConstituency" : {"_value" : "Poole"} , "tablingMemberPrinted" : [{"_value" : "Mr Robert Syms"} ], "uin" : "32262"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 7, "type" : "http://purl.org/linked-data/api/vocab#Page"} }